July 23, 2018 09:00 AM EDT

Faheem Hasnain ups cash haul to $330M for a fledgling biotech that is moving ‘at light speed’

John Carroll

Editor & Founder

Just six months ago, Faheem Hasnain rolled out his latest biotech venture with a $100 million mega-round for seed money. Today, he’s adding $230 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Faheem Hasnain ups cash haul to $330M for a fledgling biotech that is moving ‘at light speed’

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Fa­heem Has­nain ups cash haul to $330M for a fledg­ling biotech that is mov­ing ‘at light speed’

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Faheem Hasnain ups cash haul to $330M for a fledgling biotech that is moving ‘at light speed’

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test